Figure 4 | Scientific Reports

Figure 4

From: 1,25(OH)2VitD3 supplementation enhances suppression of grass pollen-induced allergic asthma by subcutaneous and sublingual immunotherapy in a mouse model

Figure 4

Overview and immunoglobulin response after VitD3-supplemented GP-SLIT. (A) Outline of the SLIT protocol. (B) Outline of the treatment groups. (C) Serum levels of total IgE (ng/mL) taken before SLIT (white bars, Pre1), after 3 weeks of SLIT (light grey bars, Pre2), after 6 weeks of SLIT (middle grey bars, Pre3), before challenge (dark grey bars, Pre4), and after challenges (black bars, Post). (D) Serum GP-spIgE (Arbitrary Units (AU)/mL, Pre1-4, Post). (E) Serum GP-spIgG1 (AU/mL, Pre1-4, Post). (F) Serum GP-spIgG2a (AU/mL, Pre1-4, Post). (G) Blocking activity plotted as ratio of GP-spIgG1/GP-spIgE in Post sera. (H) Blocking activity plotted as ratio of GP-spIgG2a/GP-spIgE in Post sera. (I) Fold induction of GP-spIgE after challenge (Post-sera/Pre2-sera). In Fig. 1C–F, values are expressed as mean ± SEM (n = 8). In Fig. 1G–I, values are expressed in Box-and-whiskers plots (min-max). NC, Negative Control, PBS challenged; PC, Positive Control, GP challenged; PCD, PC with VitD3 in SLIT (10 ng); 300, 300kSQ SLIT; 300D, 300kSQ SLIT with 10 ng VitD3. *P < 0.05, **P < 0.01, ***P < 0.001 compared to PC or PCD respectively (300 vs PC and 300D vs PCD), unless otherwise specified.

Back to article page